Drug Pipeline

Vemurafenib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
12
Active Studies
4
Recruiting
2
Phase 3
9
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-23 NCT04302025
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages…
Primary endpoint(s) modified
Active Studies by Phase
Phase 3
1
Phase 2/3
1
Phase 2
9
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT03768063 A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd… Cancer Active, Not Recruiting
Phase 2/3
NCT03178552 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments… Non-Small Cell Lung Cancer Active, Not Recruiting
Phase 2
NCT06440850 Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated… Thyroid Gland Follicular Carcinoma Recruiting
NCT04943198 Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients… Histiocytosis Recruiting
NCT06561360 A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People… Hairy Cell Leukemia Recruiting
NCT04302025 A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages… Non-small Cell Lung Cancer Recruiting
NCT03181100 Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly… Metastatic Thyroid Gland Carcinoma Active, Not Recruiting
NCT03410875 A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With… Hairy Cell Leukemia Active, Not Recruiting
NCT01709292 Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer Thyroid Cancer Active, Not Recruiting
NCT03155620 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed… Advanced Malignant Solid Neoplasm Active, Not Recruiting
NCT03224767 Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive… BRAF V600E Mutation Present Active, Not Recruiting
Phase 1
NCT02721459 XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Melanoma Active, Not Recruiting
Sponsors Running Vemurafenib Trials
Disease Areas
Get alerts when Vemurafenib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free